Clinical activity of pemphigus vulgaris relates to IgE autoantibodies against desmoglein 3

Clinical Immunology

Volumn 134, Issue 3, 2010, Pages 320-330

  Nagel, Angela ^a   Lang, Angelika ^b   Engel, Dorothee ^b   Podstawa, Eva ^a   Hunzelmann, Nicolas ^c   de Pita, Ornella ^d   Borradori, Luca ^e   Uter, Wolfgang ^b   Hertl, Michael ^a,b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^e Klinik und Poliklinik fur Dermatologie   (Switzerland)

Author keywords

Autoantibody; Desmoglein 3; IgE; IgG4; Pemphigus; T helper 2 cell

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DAPSONE; DESMOGLEIN 3; DESMOGLEIN 3 ANTIBODY; DEXAMETHASONE; IMMUNOGLOBULIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G4; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; BULLOUS SKIN DISEASE; CHILD; CHRONIC DISEASE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDERMIS; FEMALE; HUMAN; IMMUNOFLUORESCENCE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN DEPOSITION; MAJOR CLINICAL STUDY; MALE; PEMPHIGUS VULGARIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMISSION; SCHOOL CHILD; TH2 CELL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; CHILD; CHILD, PRESCHOOL; DESMOGLEIN 3; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INFANT; MALE; MIDDLE AGED; PEMPHIGUS; RECOMBINANT PROTEINS; ROC CURVE; SEX FACTORS; TH2 CELLS; YOUNG ADULT;

EID: 76049110726     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2009.11.006     Document Type: Article

References (41)

1. Bystryn J.C., and Rudolph J.L. Pemphigus. Lancet 366 (2005) 61-73
2. Hertl M. Humoral and cellular autoimmunity in autoimmune bullous skin disorders. Int. Arch. Allergy Immunol. 122 (2000) 91-100
3. Sitaru C., Mihai S., and Zillikens D. The relevance of the IgG subclass of autoantibodies for blister induction in autoimmune bullous skin diseases. Arch. Dermatol. Res. 299 (2007) 1-8
4. Ioannides D., Lazaridou E., and Rigopoulos D. Pemphigus. J. Eur. Acad. Dermatol. Venereol. 22 (2008) 1478-1496
5. Waschke J. The desmosome and pemphigus. Histochem. Cell. Biol. 130 (2008) 21-54
6. Heupel W.M., Zillikens D., Drenckhahn D., and Waschke J. Pemphigus vulgaris IgG directly inhibit desmoglein 3-mediated transinteraction. J. Immunol. 181 (2008) 1825-1834
7. Amagai M. Autoimmunity against desmosomal cadherins in pemphigus. J. Dermatol. Sci. 20 (1999) 92-102
8. Moll R., and Moll I. Epidermal adhesion molecules and basement membrane components as target structures of autoimmunity. Virchows Arch. 432 (1998) 487-504
9. Grando S.A. Autoimmunity to keratinocyte acetylcholine receptors in pemphigus. Dermatology 201 (2000) 290-295
10. Amagai M., Klaus-Kovtun V., and Stanley J.R. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 67 (1991) 869-877
11. Amagai M., Karpati S., Prussick R., Klaus-Kovtun V., and Stanley J.R. Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic. J. Clin. Invest. 90 (1992) 919-926
12. Parlowsky T., Welzel J., Amagai M., Zillikens D., and Wygold T. Neonatal pemphigus vulgaris: IgG4 autoantibodies to desmoglein 3 induce skin blisters in newborns. J. Am. Acad. Dermatol. 48 (2003) 623-625
13. Amagai M., Ahmed A.R., Kitajima Y., Bystryn J.C., Milner Y., Gniadecki R., Hertl M., Pincelli C., Kurzen H., Fridkis-Hareli M., Aoyama Y., Frusic-Zlotkin M., Muller E., David M., Mimouni D., Vind-Kezunovic D., Michel B., Mahoney M., and Grando S. Are desmoglein autoantibodies essential for the immunopathogenesis of pemphigus vulgaris, or just "witnesses of disease"?. Exp. Dermatol. 15 (2006) 815-831
14. Bhol K., Natarajan K., Nagarwalla N., Mohimen A., Aoki V., and Ahmed A.R. Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 5239-5243
15. Yeh S.W., Cavacini L.A., Bhol K.C., Lin M.S., Kumar M., Duval M., Posner M.R., and Ahmed A.R. Pathogenic human monoclonal antibody against desmoglein 3. Clin. Immunol. 120 (2006) 68-75
16. Hacker M.K., Janson M., Fairley J.A., and Lin M.S. Isotypes and antigenic profiles of pemphigus foliaceus and pemphigus vulgaris autoantibodies. Clin. Immunol. 105 (2002) 64-74
17. Ahmed A.R., Spigelman Z., Cavacini L.A., and Posner M.R. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N. Engl. J. Med. 355 (2006) 1772-1779
18. Eming R., Nagel A., Wolff-Franke S., Podstawa E., Debus D., and Hertl M. Rituximab exerts a dual effect in pemphigus vulgaris. J. Invest. Dermatol. 128 (2008) 2850-2858
19. Lin M.S., Swartz S.J., Lopez A., Ding X., Fernandez-Vina M.A., Stastny P., Fairley J.A., and Diaz L.A. Development and characterization of desmoglein-3 specific T cells from patients with pemphigus vulgaris. J. Clin. Invest. 99 (1997) 31-40
20. Geha R.S., Jabara H.H., and Brodeur S.R. The regulation of immunoglobulin E class-switch recombination. Nat. Rev. Immunol. 3 (2003) 721-732
21. Aalberse R.C., Stapel S.O., Schuurman J., and Rispens T. Immunoglobulin G4: an odd antibody. Clin. Exp. Allergy 39 (2009) 469-477
22. Veldman C., Stauber A., Wassmuth R., Uter W., Schuler G., and Hertl M. Dichotomy of autoreactive Th1 and Th2 cell responses to desmoglein 3 in patients with pemphigus vulgaris (PV) and healthy carriers of PV-associated HLA class II alleles. J. Immunol. 170 (2003) 635-642
23. Rizzo C., Fotino M., Zhang Y., Chow S., Spizuoco A., and Sinha A.A. Direct characterization of human T cells in pemphigus vulgaris reveals elevated autoantigen-specific Th2 activity in association with active disease. Clin. Exp. Dermatol. 30 (2005) 535-540
24. Caproni M., Giomi B., Cardinali C., Salvatore E., Pestelli E., D'Agata A., Bianchi B., Toto P., Feliciani C., and Fabbri P. Further support for a role for Th2-like cytokines in blister formation of pemphigus. Clin. Immunol. 98 (2001) 264-271
25. Dopp R., Schmidt E., Chimanovitch I., Leverkus M., Brocker E.B., and Zillikens D. IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity. J. Am. Acad. Dermatol. 42 (2000) 577-583
26. Dresow S.K., Sitaru C., Recke A., Oostingh G.J., Zillikens D., and Gibbs B.F. IgE autoantibodies against the intracellular domain of BP180. Br. J. Dermatol. 160 (2009) 429-432
27. Iwata Y., Komura K., Kodera M., Usuda T., Yokoyama Y., Hara T., Muroi E., Ogawa F., Takenaka M., and Sato S. Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid. Arch. Dermatol. 144 (2008) 41-48
28. Dimson O.G., Giudice G.J., Fu C.L., Van den Bergh F., Warren S.J., Janson M.M., and Fairley J.A. Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid. J. Invest. Dermatol. 120 (2003) 784-788
29. Spaeth S., Riechers R., Borradori L., Zillikens D., Budinger L., and Hertl M. IgG, IgA and IgE autoantibodies against the ectodomain of desmoglein 3 in active pemphigus vulgaris. Br. J. Dermatol. 144 (2001) 1183-1188
30. Ishii K., Amagai M., Hall R.P., Hashimoto T., Takayanagi A., Gamou S., Shimizu N., and Nishikawa T. Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J. Immunol. 159 (1997) 2010-2017
31. Kemeny D.M. Titration of antibodies. J. Immunol. Methods 150 (1992) 57-76
32. Gebhard K.L., Veldman C.M., Wassmuth R., Schultz E., Schuler G., and Hertl M. Ex vivo analysis of desmoglein 1-responsive T-helper (Th) 1 and Th2 cells in patients with pemphigus foliaceus and healthy individuals. Exp. Dermatol. 14 (2005) 586-592
33. Takahashi H., Amagai M., Nishikawa T., Fujii Y., Kawakami Y., and Kuwana M. Novel system evaluating in vivo pathogenicity of desmoglein 3-reactive T cell clones using murine pemphigus vulgaris. J. Immunol. 181 (2008) 1526-1535
34. Takahashi H., Amagai M., Tanikawa A., Suzuki S., Ikeda Y., Nishikawa T., Kawakami Y., and Kuwana M. T helper type 2-biased natural killer cell phenotype in patients with pemphigus vulgaris. J. Invest. Dermatol. 127 (2007) 324-330
35. Iciek L.A., Delphin S.A., and Stavnezer J. CD40 cross-linking induces Ig epsilon germline transcripts in B cells via activation of NF-kappaB: synergy with IL-4 induction. J. Immunol. 158 (1997) 4769-4779
36. Aoki-Ota M., Kinoshita M., Ota T., Tsunoda K., Iwasaki T., Tanaka S., Koyasu S., Nishikawa T., and Amagai M. Tolerance induction by the blockade of CD40/CD154 interaction in pemphigus vulgaris mouse model. J. Invest. Dermatol. 126 (2006) 105-113
37. Eming R., Hertl M., Schmidt J., Podstawa E., Feliciani C., and Sonderstrup G. T-B interaction is crucial for the induction of desmoglein3-specific IgG autoantibodies in an HLA-class II transgenic mouse model of pemphigus vulgaris. J. Invest. Dermatol. 127 (2007) S66
38. Delaporte E., Dubost-Brama A., Ghohestani R., Nicolas J.F., Neyrinck J.L., Bergoend H., Janin A., and Capron M. IgE autoantibodies directed against the major bullous pemphigoid antigen in patients with a severe form of pemphigoid. J. Immunol. 157 (1996) 3642-3647
39. Budinger L., Borradori L., Yee C., Eming R., Ferencik S., Grosse-Wilde H., Merk H.F., Yancey K., and Hertl M. Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls. J. Clin. Invest. 102 (1998) 2082-2089
40. Fairley J.A., Burnett C.T., Fu C.L., Larson D.L., Fleming M.G., and Giudice G.J. A pathogenic role for IgE in autoimmunity: bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu/nu mice. J. Invest. Dermatol. 127 (2007) 2605-2611
41. Fairley J.A., Baum C.L., Brandt D.S., and Messingham K.A. Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab. J. Allergy Clin. Immunol. 123 (2009) 704-705